entertainment -WSS

entertainment

author：knowledge 2025-09-27 23:32:35 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Awakening the world to the whoosh: A patient's crusade

entertainment

WSS

Stanford president faces new allegations over 1999 paper

Affordable Connectivity Program vital to health care, experts say

Why Congress must ban federal programs from using QALYs

I learned firsthand about improving diversity in clinical trials

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Tesla recalling nearly 16,000 of its 2021

focus

entertainment

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Sanofi strikes deal with Novavax, boosting the vaccine maker

Duchenne breakthrough therapy leaves behind pioneering families

What nurses really want: sufficient staffing for patient care

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: brain research, obesity drug sales, Novartis

After affirmative action ruling, medical educators look to 'holistic review'

Dairy farmers resist CDC push for PPE against bird flu virus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

hotspot

Judge rejects Trump's request to move Stormy Daniels hush

Sanofi strikes deal with Novavax, boosting the vaccine maker

Hospitals struggle to profit from CAR

Stanford president faces new allegations over 1999 paper

Bird flu outbreak in cows is latest avian flu curveball

7 more heat

hotspot

entertainment

leisure time

leisure time